Artemis II Success Puts NASA's Moon Landing in SpaceX's Hands

Cover image from washingtonexaminer.com, which was analyzed for this article
America's next lunar mission under the Artemis program relies significantly on Elon Musk and SpaceX capabilities, raising questions of dependency. Astronaut Victor Glover, part of the program, exemplifies commitment amid preparations. The initiative advances US space ambitions despite challenges.
PoliticalOS
Saturday, April 18, 2026 — Tech
Artemis II successfully demonstrated NASA's ability to send astronauts around the moon again, with Victor Glover exemplifying the skill and personal dedication required. The landing missions that follow now hinge on SpaceX delivering a human-rated lander on an aggressive schedule, even as NASA operates with 20 percent fewer staff and reduced internal oversight capacity. The central question is whether the innovation gains from this public-private model outweigh the risks of depending so heavily on one company and one individual.
What outlets missed
Both articles omitted the broader international dimension of Artemis, including contributions from the European Space Agency, Japan and Canada to Orion and other hardware that reduce sole dependence on U.S. contractors. Coverage also underplayed how SpaceX's prior Crew-1 flight with Glover himself demonstrated years of successful NASA-commercial integration rather than a sudden shift. Neither piece examined the Space Launch System rocket — developed in-house by NASA at far higher cost — which remains the program's primary heavy-lift vehicle and is not supplied by Musk. The Washington Examiner ignored all financial, workforce and scheduling data, while Mother Jones gave minimal space to the verified engineering achievements that made Artemis II possible on revised timelines.
You've seen the spin. Now read what happened.
The unbiased version strips away everything the other four added: the framing, the omissions, the selective emphasis. Just what happened.
Read all five, free for 7 days$4.99/mo after trial. Cancel anytime.